The estimated Net Worth of R. Scott Areglado is at least $125 Mille dollars as of 8 December 2020. Mr. Areglado owns over 15,000 units of Icad Inc stock worth over $72,156 and over the last 8 years he sold ICAD stock worth over $52,450. In addition, he makes $0 as Chief Financial Officer at Icad Inc.
Sign up
Mr. Areglado ICAD stock SEC Form 4 insiders trading
R has made over 2 trades of the Icad Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ICAD stock worth $90,000 on 8 December 2020.
The largest trade he's ever made was exercising 15,000 units of Icad Inc stock on 8 December 2020 worth over $90,000. On average, R trades about 2,222 units every 11 days since 2016. As of 8 December 2020 he still owns at least 51,911 units of Icad Inc stock.
You can see the complete history of Mr. Areglado stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. Scott Areglado biography
R. Scott Areglado serves as Chief Financial Officer of the Company. He has served as the Company’s Chief Financial Officer since May 2019. From May 2011 until December 2018, Mr. Areglado served as Company’s Vice President and Corporate Controller, and from December 2018 to May 2019 and September to November 2016, he served as interim Chief Financial Officer. From 2005 to 2010, Mr. Areglado served as Vice President and Controller at AMICAS, Inc., a Nasdaq-listed image and information management solutions company serving the healthcare industry, where he led financial statement preparation and accounting operations for the company. Mr. Areglado has more than 25 years of experience in finance and accounting and was a licensed Certified Public Accountant from 1990 to 2007. Mr. Areglado received an M.B.A. degree from the Franklin W. Olin Graduate School of Business at Babson College and a Bachelor of Business Administration degree in Accounting from the University of Massachusetts, Amherst.
What's R Areglado's mailing address?
R's mailing address filed with the SEC is 98 Spit Brook Rd, Nashua, NH 03062, USA.
Insiders trading at Icad Inc
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton e Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
What does Icad Inc do?
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
What does Icad Inc's logo look like?
Complete history of Mr. Areglado stock trades at Icad Inc
Icad Inc executives and stock owners
Icad Inc executives and other stock owners filed with the SEC include:
-
Michael S. Klein,
Exec. Chairman & CEO -
Stacey Stevens,
President -
Jonathan Go,
Chief Technology Officer -
Michael Klein,
Executive Chairman of the Board, Chief Executive Officer -
Stacey M. Stevens,
Pres -
Jonathan Go,
Chief Technology Officer -
Andrew Sassine,
Independent Director -
Susan Wood,
Independent Director -
Rakesh Patel,
Independent Director -
Jeremy Feffer,
Investor Relations Contact Officer -
Nathaniel Dalton,
Independent Director -
R. Scott Areglado,
Chief Financial Officer -
Jeffrey Sirek,
Chief Commercial Officer -
Brian Testa,
Chief People Officer -
Annette L. Heroux,
VP of Admin. -
Charles Ross Carter,
CFO & Sec. -
Rachel Brem,
Director -
Steven N Rappaport,
Director -
Robert L Goodman,
Director -
Dr Lawrence Howard,
Director -
Anthony F Ecock,
Director -
Timothy Norris Irish,
Director -
Richard Christopher,
Executive VP and CFO -
Andy Sassine,
Director -
Somu Subramaniam,
Director -
Elliot J Md Mba Sussman,
Director -
Kenneth M Ferry,
President, CEO -
James Harlan,
Director -
George P Farley,
Director -
W Scott Parr,
Chief Executive Officer, Presi -
Herschell Sklaroff,
Director -
John De Biase,
Vice President of Sales -
Annette Heroux,
Chief Financial Officer -
Steven K Rogers,
Chief Scientific Officer -
Peter Farrell,
EVP Marketing -
Thomas E Shoup,
VP, Staff Operations -
James L Corbett,
Chief Commercial Officer -
Kevin Woods,
Vice President, Research & Dev -
Samuel Ronci,
Vice President of Operations -
Robert Howard,
Director -
Kevin C Burns,
Executive VP of Finance, CFO -
Darlene M Deptula Hicks,
Executive VP of Finance, CFO -
Maha Sallam,
Executive Vice President -
Jeffrey H Barnes,
Executive VP of Sales -
Dana R Brown,
See Remarks -
Charles Ross Carter,
CHIEF FINANCIAL OFFICER -
Hedvig Hricak,
Director -
Daniel Joseph Shea,
See Remarks -
Eric Lonnqvist,
See Remarks -
Michael John Doyle,
Director